Ivabradine

CHEMBL471737 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

468.6 g/mol

LogP

2.4

Phase

4

This unique heart rate-lowering drug selectively inhibits the If current ("funny current") in the sinoatrial node of the heart, reducing heart rate without affecting blood pressure or cardiac contractility. It is used to treat stable angina and symptomatic heart failure with reduced ejection fraction in patients with elevated resting heart rate. It is particularly useful in patients who cannot tolerate beta-blockers.

Masse moléculaire

468,6000 g/mol

LogP

2,40

TPSA

60,50 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Asthma Chronic Obstructive Pulmonary Disease Migraine Schizophrenia Non-Alcoholic Fatty Liver Disease Oncology Lymphoma Hypertension Heart Failure Atrial Fibrillation Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2

InChI

InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1

Molecular Formula

C27H36N2O5

HBD / HBA

- / 6

Liaisons Rotatives

10

Atomes Lourds

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This unique heart rate-lowering drug selectively inhibits the If current ("funny current") in the sinoatrial node of the heart, reducing heart rate without affecting blood pressure or cardiac contractility. It is used to treat stable angina and symptomatic heart failure with reduced ejection fraction in patients with elevated resting heart rate. It is particularly useful in patients who cannot tolerate beta-blockers.

Yes, Ivabradine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL471737. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 132999. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Ivabradine sur PillFYI

Structure

Données Clés

Formule: C27H36N2O5
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.